Clinical Trial Update: Radioimmunotherapy with Lu-177 Labeled 6A10 Fab-fragments in Patients with Glioblastoma After Standard Treatment [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Lu-177 labeled 6A10 Fab fragments for glioblastoma after standard treatment. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Lu-177-labeled 6A10 Fab-fragments (lutetium-177-labeled 6A10 Fab fragment)

Snippet

Sponsor: University Hospital Muenster | Conditions: Glioblastom WHO Grade 4 | Phase 1 | Status: RECRUITING